Cargando…
Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
Psoriasis is a common inflammatory skin condition frequently associated with cardiometabolic diseases such as diabetes. Indeed, the state of systemic inflammation typical of psoriasis leads to an increase in the level of IL-1, IL-6 and TNF-alpha which may cause a reduced sensitivity to insulin and,...
Autores principales: | Lanna, Caterina, Cesaroni, Gaia Maria, Mazzilli, Sara, Bianchi, Luca, Campione, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925552/ https://www.ncbi.nlm.nih.gov/pubmed/31908509 http://dx.doi.org/10.2147/DMSO.S229549 |
Ejemplares similares
-
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
por: Afra, T. P., et al.
Publicado: (2019) -
The Effectiveness of a New Topical Formulation Containing GSH-C4 and Hyaluronic Acid in Seborrheic Dermatitis: Preliminary Results of an Exploratory Pilot Study
por: Campione, Elena, et al.
Publicado: (2019) -
Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis
por: Caputo, Valerio, et al.
Publicado: (2021) -
Experimental Pharmacological Management of Psoriasis
por: Campione, Elena, et al.
Publicado: (2021) -
Microbiota and Glucidic Metabolism: A Link with Multiple Aspects and Perspectives
por: Ciarambino, Tiziana, et al.
Publicado: (2023)